2010
Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial
Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, Burman WJ, MacArthur RD, Chesney M, Friedland G, Mannheimer SB. Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS 2010, 24: 395-403. PMID: 20099399, PMCID: PMC2886717, DOI: 10.1097/qad.0b013e328335cd8a.Peer-Reviewed Original ResearchConceptsInitial virological failureCumulative adherenceVirological failureMedian timeNucleoside reverse transcriptase inhibitor resistanceProspective clinical trial dataInhibitor strategiesLarge prospective clinical trialsReverse transcriptase inhibitor resistanceInhibitor resistanceAntiretroviral-naive participantsProspective clinical trialsCox regression analysisTranscriptase inhibitor resistanceAntiretroviral medication adherenceProtease inhibitor resistanceClinical trial dataProtease inhibitorsMedication resistanceAntiretroviral therapyHIV RNANNRTI resistanceMedication adherenceClinical trialsGenotypic resistance
2008
Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance
Gardner EM, Sharma S, Peng G, Hullsiek KH, Burman WJ, MacArthur RD, Chesney M, Telzak EE, Friedland G, Mannheimer SB. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008, 22: 75-82. PMID: 18090394, PMCID: PMC2405889, DOI: 10.1097/qad.0b013e3282f366ff.Peer-Reviewed Original ResearchConceptsNon-nucleoside reverse transcriptase inhibitorInitial virological failureCombination antiretroviral therapyVirological failureAntiretroviral resistanceAntiretroviral therapyTreatment-naive HIV-1-infected individualsDifferential adherenceProspective clinical trial dataHIV-1-infected individualsMultivariate Cox regression analysisProtease inhibitorsTime-updated variablesCox regression analysisDisease-specific factorsReverse transcriptase inhibitorClinical trial dataMedication resistanceAntiretroviral medicationsRandomized trialsMonths 1Transcriptase inhibitorSame timepointsTrial dataSecondary analysis
2004
Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir
McCance‐Katz E, Rainey PM, Smith P, Morse G, Friedland G, Gourevitch M, Jatlow P. Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir. American Journal On Addictions 2004, 13: 163-180. PMID: 15204667, DOI: 10.1080/10550490490436037.Peer-Reviewed Original ResearchConceptsDrug interactionsMetabolite exposureClinical pharmacology studiesInjection drug usersNelfinavir concentrationsOpiate medicationsOpiate therapyMethadone exposureAntiretroviral medicationsHIV outcomesDay study periodPharmacology studiesDrug usersMethadoneNelfinavirLAAMStudy periodMedicationsMinimal overall changeProtease inhibitorsExposureToxicityOverall changeAntiretroviralsOpioids
2003
The Protease Inhibitor Lopinavir-Ritonavir May Produce Opiate Withdrawal in Methadone-Maintained Patients
McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The Protease Inhibitor Lopinavir-Ritonavir May Produce Opiate Withdrawal in Methadone-Maintained Patients. Clinical Infectious Diseases 2003, 37: 476-482. PMID: 12905130, DOI: 10.1086/376907.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirMethadone metabolismSubstance abuse pharmacotherapyOpiate withdrawal symptomsInjection drug usersConcentration-time curveMethadone areaMethadone dosesHIV diseaseMethadone concentrationsOral clearancePharmacodynamic interactionsWithdrawal symptomsOpiate withdrawalClinical monitoringDrug usersSame dosageRitonavirPotent inducerPatientsMethadoneProtease inhibitorsSignificant reductionR formulationTreatment